openPR Logo
Press release

Primary Biliary Cholangitis Therapeutics Market Size in the 7MM was over further expected to increase by 2034, estimates DelveInsight

12-23-2024 11:18 PM CET | Health & Medicine

Press release from: ABNewswire

Primary Biliary Cholangitis Therapeutics Market Size in the 7MM

DelveInsight's "Primary Biliary Cholangitis Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Primary Biliary Cholangitis, historical and forecasted epidemiology as well as the Primary Biliary Cholangitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover which therapies are expected to grab the Primary Biliary Cholangitis Market Share @ Primary Biliary Cholangitis Market Outlook [https://www.delveinsight.com/sample-request/primary-biliary-cholongitis-pbc-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways form the Primary Biliary Cholangitis Market Report

* DelveInsight's forecasting report of PBC includes the Epidemiology analysis and forecast of the US, EU4 and the UK, and Japan. As per our analysis, the US had the highest diagnosed prevalent cases of PBC in 2023, which are expected to rise, at a decent CAGR during the forecasted period (2024-2034).
* In 2023, among EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Germany accounted for the highest number of diagnosed prevalent cases of PBC i.e. around 34 thousand cases which is expected to increase by 2034.
* The incidence of PBC rises with age, and is particularly higher among individuals aged 40 to 70 years. Our estimates for 2023 indicate a distribution of cases by age groups: approximately 14 thousand cases were observed in individuals under 40 years old, with numbers increasing steadily with age. The highest number of cases, totaling 87 thousand, occurred in the 40-70 age bracket, while 43 thousand cases were reported in individuals aged 70 and above in the US.
* Our analysis indicates a higher prevalence of PBC among females compared to males, with distribution rates of 82% and 18% respectively, in the US in 2023.
* The leading Primary Biliary Cholangitis Companies such as Intercept Pharmaceuticals, CymaBay Therapeutics, Genfit, Genkyotex SA, Zydus Cadila, Cara Therapeutics, HighTide Therapeutics, Albireo, GlaxoSmithKline , and others.
* Promising Primary Biliary Cholangitis Therapies such as Elafibranor, Saroglitazar Magnesium, CNP-104, Setanaxib, Seladelpar, Volixibat, Bezafibrate, EP547, Linerixibat , and others.

Navigate the complexities of the Primary Biliary Cholangitis Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Primary Biliary Cholangitis Market Forecast. Click here to get more insights @ Primary Biliary Cholangitis Treatment Market [https://www.delveinsight.com/sample-request/primary-biliary-cholongitis-pbc-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Primary Biliary Cholangitis Epidemiology Segmentation in the 7MM

* Total Primary Biliary Cholangitis Diagnosed Prevalent Cases
* Primary Biliary Cholangitis Gender-specific Cases
* Primary Biliary Cholangitis Age-specific Cases

Download the report to understand which factors are driving Primary Biliary Cholangitis Epidemiology trends @ Primary Biliary Cholangitis Prevalence [https://www.delveinsight.com/sample-request/primary-biliary-cholongitis-pbc-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Primary Biliary Cholangitis Marketed Drugs

* OCALIVA: Intercept Pharmaceuticals

OCALIVA offers a novel treatment approach for PBC by targeting FXR and has shown efficacy in reducing ALP levels and improving outcomes for patients who have not responded to or cannot tolerate UDCA, highlighting its significance as an alternative therapy in the management of PBC. OCALIVA has received accelerated approval from the FDA for the treatment of PBC, demonstrating its potential to address serious conditions and providing earlier patient access to promising new drugs while confirmatory trials are ongoing.

Primary Biliary Cholangitis Emerging Drugs

* Seladelpar: CymaBay Therapeutics

Seladelpar, developed by CymaBay Therapeutics, is an oral, selective peroxisome proliferator-activated receptor (PPAR) delta agonist aimed at treating primary biliary cholangitis (PBC). It regulates crucial metabolic and liver disease pathways, impacting bile acid synthesis, inflammation, fibrosis, and lipid metabolism. Clinical studies demonstrate its efficacy in reducing biomarkers associated with adverse outcomes in PBC, alongside improving pruritus. Unlike other PPAR agonists, seladelpar acts on various liver cell types, uniquely affecting PBC pathobiology. It has garnered FDA Breakthrough Therapy Designation and EMA Priority Medicines (PRIME) status, with an NDA submitted to the FDA for PBC treatment, underscoring its promising potential and regulatory recognition.

Get In-Depth Knowledge on Primary Biliary Cholangitis Market Trends and Forecasts with DelveInsight @ Primary Biliary Cholangitis Treatment Market [https://www.delveinsight.com/sample-request/primary-biliary-cholongitis-pbc-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Primary Biliary Cholangitis Treatment Market

Treatment objectives aim to decelerate the advancement of the disease and alleviate associated symptoms such as itching, osteoporosis, and sicca syndrome. Liver transplantation stands as the singular life-saving procedure available. Ursodeoxycholic acid (UDCA) stands as the primary medication employed to impede disease progression. Patients in the initial stages of the disease witness clinical, biochemical, and histological enhancements. Studies indicate that UDCA postpones the necessity for transplantation and prolongs life. However, its effectiveness in later stages, particularly in cases of cirrhosis, remains uncertain.

Primary Biliary Cholangitis Companies

Intercept Pharmaceuticals, CymaBay Therapeutics, Genfit, Genkyotex SA, Zydus Cadila, Cara Therapeutics, HighTide Therapeutics, Albireo, GlaxoSmithKline, and others.

Scope of the Primary Biliary Cholangitis Market Report

* Coverage- 7MM
* Study Period- 2020-2034
* Primary Biliary Cholangitis Companies- Intercept Pharmaceuticals, CymaBay Therapeutics, Genfit, Genkyotex SA, Zydus Cadila, Cara Therapeutics, HighTide Therapeutics, Albireo, GlaxoSmithKline, and others.
* Primary Biliary Cholangitis Therapies- Elafibranor, Saroglitazar Magnesium, CNP-104, Setanaxib, Seladelpar, Volixibat, Bezafibrate, EP547, Linerixibat, and others.
* Primary Biliary Cholangitis Market Dynamics: Primary Biliary Cholangitis Market Drivers and Barriers
* Primary Biliary Cholangitis Unmet Needs, KOL's views, Analyst's views, Primary Biliary Cholangitis Market Access and Reimbursement

Gain a strategic edge in the Primary Biliary Cholangitis Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Primary Biliary Cholangitis Market Forecast. Click here to lead in advancements @ Primary Biliary Cholangitis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/primary-biliary-cholongitis-pbc-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1. Key Insights

2. Executive Summary of Primary Biliary Cholangitis

3. Competitive Intelligence Analysis for Primary Biliary Cholangitis

4. Primary Biliary Cholangitis: Market Overview at a Glance

5. Primary Biliary Cholangitis: Disease Background and Overview

6. Patient Journey

7. Primary Biliary Cholangitis Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Primary Biliary Cholangitis Unmet Needs

10. Key Endpoints of Primary Biliary Cholangitis Treatment

11. Primary Biliary Cholangitis Marketed Products

12. Primary Biliary Cholangitis Emerging Therapies

13. Primary Biliary Cholangitis: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Primary Biliary Cholangitis Market Outlook

16. Access and Reimbursement Overview of Primary Biliary Cholangitis

17. Primary Biliary Cholangitis KOL Views

18. Primary Biliary Cholangitis Market Drivers

19. Primary Biliary Cholangitis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=primary-biliary-cholangitis-therapeutics-market-size-in-the-7mm-was-over-further-expected-to-increase-by-2034-estimates-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Primary Biliary Cholangitis Therapeutics Market Size in the 7MM was over further expected to increase by 2034, estimates DelveInsight here

News-ID: 3796128 • Views:

More Releases from ABNewswire

Best Deals on 2025 Milwaukee Bucks NBA Tickets - Use Promo CITY10 Online at CapitalCityTickets.com
Best Deals on 2025 Milwaukee Bucks NBA Tickets - Use Promo CITY10 Online at Capi …
Get the best deals on 2025 Milwaukee Bucks tickets at CapitalCityTickets.com! Choose from a wide selection of seat levels and enjoy even greater savings by applying promo code CITY10 at checkout. Secure your tickets now and cheer on the Bucks live at Fiserv Forum or on the road-while seats last! Looking for the best deals on Milwaukee Bucks NBA tickets for the 2025-26 season? You can score affordable tickets to see
Affordable Montreal Canadiens Bell Centre Tickets Online - Save with Promo Code CITY10 on the Best Site CapitalCityTickets.com
Affordable Montreal Canadiens Bell Centre Tickets Online - Save with Promo Code …
Score affordable Montreal Canadiens tickets at Bell Centre! Use promo code CITY10 at CapitalCityTickets.com to save on your seats. Compare ticket options, find the best views, and secure your spot to watch the Canadiens live. Don't miss top NHL action-grab discounted tickets today and enjoy thrilling hockey games without overspending! As the 2025-26 NHL season ignites, the Montreal Canadiens are gearing up to light up the Bell Centre with their signature
Central Florida Notary Express, LLC Expands 24/7 Notary and Mobile Notary Services Across Greater Orlando
Central Florida Notary Express, LLC Expands 24/7 Notary and Mobile Notary Servic …
Winter Park, FL - Central Florida Notary Express, LLC, a 24/7 provider of notary and mobile notary services and certified loan signings, announced expanded same-day coverage across the Greater Orlando area, including Orlando, Winter Park, Maitland, Casselberry, Winter Springs, DeLand, DeBary, Deltona, Sanford, and Lake Mary. The company offers on-site and curbside notarization for jurats, acknowledgments, power of attorney (POA), wills, health care surrogate forms, copy certifications, and real-estate loan
Stafili Wine Cafe Brings the Heart of Greece to New York City - A Sophisticated Destination for Wine Lovers and Food Enthusiasts
Stafili Wine Cafe Brings the Heart of Greece to New York City - A Sophisticated …
Nestled in the vibrant neighborhoods of West Village and Tribeca, Stafili Wine Cafe is redefining New York's dining scene with an unforgettable Greek-inspired experience that blends exceptional wines, authentic Mediterranean cuisine, and an inviting, intimate atmosphere. Whether you're seeking a cozy date night, an after-work escape, or a refined venue for social gatherings, Stafili promises an indulgent journey through the flavors, aromas, and spirit of Greece - without ever leaving

All 5 Releases


More Releases for Primary

Premier Primary Care Medicine Recognized as Top-Rated Primary Care Physician in …
Premier Primary Care Medicine has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible, high-quality primary care, same-day and next-day appointments, and an approach centered on long-term patient relationships. Marietta, GA - September 16, 2025 - Premier Primary Care Medicine [https://www.premierpcmed.com/] has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible,
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd. InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy Email primaryhealthcare@pulsusgathering.org On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5% Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include: 1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk